Inhalable PD-L1-engineered hybrid cellular vesicles suppress excessive neutrophil activation and restore mitochondrial homeostasis to alleviate ischemia-reperfusion lung injury and pneumonia - PubMed
5 hours ago
- #lung injury
- #mitochondrial homeostasis
- #PD-L1-engineered vesicles
- Development of inhalable PD-L1-engineered hybrid cellular vesicles (Res-PD-L1@nmEVs) to treat lung ischemia-reperfusion injury and pneumonia.
- Res-PD-L1@nmEVs combine neutrophil membrane-derived vesicles, PD-L1-overexpressing mesenchymal stem cell extracellular vesicles, and resveratrol for multi-target therapy.
- The system enhances pulmonary accumulation, inhibits inflammation and oxidative stress, reduces apoptosis, and restores mitochondrial integrity via PINK1-mediated mitophagy.
- PD-L1 delivery suppresses neutrophil activation by binding to PD-1, reducing inflammatory cytokine release.
- Effective in rat models, improving lung tissue damage, alveolar barrier integrity, and pulmonary function while alleviating hypoxemia.
- Transcriptomic analysis shows enhanced energy metabolism and biosynthetic processes with suppressed inflammatory pathways.
- Potential for clinical translation in treating inflammatory lung diseases by addressing immune dysregulation, oxidative damage, and metabolic dysfunction.